VISTAGEN THERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Increase (Decrease) in Accounts Receivable of $106.20 thousand for the 12-month period ending 2013-03-31, per its 10-K filed 2014-06-25.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2014-06-25
- VISTAGEN THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2013-03-31 was $0.00.
- VISTAGEN THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2012-12-31 was $0.00, a 100.00% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2012-09-30 was $0.00, a 100.00% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2012-06-30 was $106.20K.
- VISTAGEN THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2013 was $106.20K.
- VISTAGEN THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2012 was -$64.00K, a 131.22% decline from fiscal 2011.
- VISTAGEN THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2011 was $205.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 3 month as first filed | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 6 month as first filed | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 9 month as first filed | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 157 month | Increase (Decrease) in Accounts Receivable 160 month | Increase (Decrease) in Accounts Receivable 163 month | Increase (Decrease) in Accounts Receivable 166 month |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-06-25 | $0.00 derived: sum of 2 quarters · filed 2014-06-25 | $0.00 derived: sum of 3 quarters · filed 2014-06-25 | $106.20K 10-K · filed 2014-06-25 | |||||||
| 2012-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-02-14 | $0.00 derived: sum of 2 quarters · filed 2014-02-14 | $106.20K 10-Q · filed 2014-02-14 | $7.80K derived: sum of 4 quarters · filed 2014-02-14 | |||||||
| 2012-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-11-14 | $106.20K 10-Q · filed 2013-11-14 | $7.80K derived: sum of 3 quarters · filed 2013-11-14 | $127.00K derived: sum of 4 quarters · filed 2013-11-14 | |||||||
| 2012-06-30 | $106.20K 10-Q · filed 2013-08-14 | $7.80K derived: sum of 2 quarters · filed 2013-08-14 | $127.00K derived: sum of 3 quarters · filed 2013-08-14 | $148.50K derived: sum of 4 quarters · filed 2013-08-14 | |||||||
| 2012-03-31 | -$98.40K derived: 10-K 12 month − 10-Q 9 month · filed 2013-07-18 | $20.80K derived: sum of 2 quarters · filed 2013-07-18 | $42.30K derived: sum of 3 quarters · filed 2013-07-18 | -$64.00K 10-K · filed 2013-07-18 | -$106.20K 10-K · filed 2012-07-02 | ||||||
| 2011-12-31 | $119.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-02-14 | $140.70K derived: sum of 2 quarters · filed 2013-02-14 | $34.40K 10-Q · filed 2013-02-14 | -$34.44K 10-Q · filed 2012-02-14 | $231.17K derived: sum of 4 quarters · filed 2013-02-14 | $7.78K 10-Q · filed 2012-02-14 | |||||
| 2011-09-30 | $21.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-11-14 | -$84.80K 10-Q · filed 2012-11-14 | $84.84K 10-Q · filed 2011-11-14 | $111.97K derived: sum of 3 quarters · filed 2012-11-14 | -$77.67K derived: sum of 4 quarters · filed 2012-11-14 | $127.06K 10-Q · filed 2011-11-14 | |||||
| 2011-06-30 | -$106.30K 10-Q · filed 2012-08-14 | $106.31K 10-Q · filed 2011-08-22 | $90.47K derived: sum of 2 quarters · filed 2012-08-14 | -$99.17K derived: sum of 3 quarters · filed 2012-08-14 | -$98.33K derived: sum of 4 quarters · filed 2012-08-14 | $148.53K 10-Q · filed 2011-08-22 | |||||
| 2011-03-31 | $196.77K derived: 10-K 12 month − 10-Q 9 month · filed 2012-07-02 | $7.13K derived: sum of 2 quarters · filed 2012-07-02 | $7.97K derived: sum of 3 quarters · filed 2012-07-02 | $205.00K 10-K · filed 2012-07-02 | |||||||
| 2010-12-31 | -$189.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-14 | -$188.81K derived: sum of 2 quarters · filed 2012-02-14 | $8.23K 10-Q · filed 2012-02-14 | ||||||||
| 2010-09-30 | $841.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2011-11-14 | $197.87K 10-Q · filed 2011-11-14 | |||||||||
| 2010-06-30 | $197.03K 10-Q · filed 2011-08-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |